UCB SA (OTCMKTS:UCBJY) Stock Short Interest Report for October

UCB SA (OTCMKTS:UCBJY) was the recipient of a large growth in short interest in October. As of October 15th, there was short interest totaling 21,017 shares, a growth of 88.6% from the September 30th total of 11,143 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 108,523 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Jefferies Financial Group upgraded UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. Zacks Research raised shares of UCB from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 27th. Two research analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, UCB presently has a consensus rating of “Buy”.

UCB Stock Performance

Shares of UCBJY stock opened at $156.80 on Monday. UCB has a 1-year low of $110.55 and a 1-year high of $168.76. The stock’s fifty day simple moving average is $124.37 and its 200-day simple moving average is $140.17.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases in neurology and immunology. The company serves patients and healthcare professionals internationally, with operations and commercial activities spanning Europe, North America and other global markets.

UCB’s neurology portfolio includes medicines such as Vimpat (lacosamide) and Briviact (brivaracetam) for epilepsy, as well as Fintepla (fenfluramine) for certain seizure disorders.